Confident management
Mesoblast has raised cash and cleared an interim futility analysis of its Phase III heart failure (HF) trial, will complete enrolment in H218 vs...
177 Views
Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
199 Views
Funding to deliver key data in 2017
Mesoblast has raised US$40m (gross) through a placement of 26.25m shares at A$2.00/share. The cash enables continued funding of the key MPC-150-IM...
147 Views
Continued positive RA responses
Statistically significant area under the curve analysis from Mesoblast’s Phase II stem cell product in refractory rheumatoid arthritis (RA) shows...
152 Views
Longs & Shorts from Sohn Sydney Conference
With all the political excitement last week, the first Sohn Sydney conference on 11th November does not appear to have received much airtime within...
459 Views